Should You Buy Shares of Intuitive Surgical In February?

Intuitive Surgical placed 532 da Vinci systems in Q4 2025 (up from 493 in Q4 2024), taking the global installed base to 11,106 systems (+12% YoY); procedures using the platform rose 18% YoY. Hardware sales accounted for ~25% of 2025 revenue (24% in 2024), instruments & accessories ~60%, services ~15%, and roughly 75% of revenue is recurring; management projects surgery/procedure growth of up to 15% in 2026. The company won late-2025 FDA approval for an AI visual-enhancement tool for lung biopsies, underscoring AI-driven product initiatives, but shares trade at a rich ~67x P/E (five-year average ~72x) implying investors must accept volatility and a long time horizon.

Analysis

Market structure: ISRG is the clear winner — 11,106 installed da Vinci systems (+12% y/y) and procedures +18% imply rising attach rates and recurring revenue (≈75% of sales, instruments ≈60%) that sustain high gross margins and pricing power on consumables. Hospitals and OR-equipment lessors benefit from improved throughput; legacy device makers (MDT, ZBH, SYK) face share pressure in robotizable procedures. Demand outpacing base (procedures +18% vs systems +12%) signals increasing utilization per unit and a multi-year consumables tailwind; higher rates would compress valuation multiples and slow hospital capex.

Risk assessment: Tail risks include an adverse AI/autonomy failure or major adverse event triggering FDA/regulatory clampdowns and liability suits, a Medicare reimbursement retreat, or a >30% capex freeze in hospitals during a recession. Short-term (days–months) sensitivity will show in placements and guidance; medium-term (12–24 months) is driven by AI approvals and procedure cadence; long-term (3–5 years) is adoption of autonomy. Hidden dependencies: attach rate relies on OR scheduling, surgeon training, and hospital leasing access; swings in any create lumpy recurring revs.

Trade implications: For concentrated exposure, consider a 2–3% portfolio long in ISRG (ticker ISRG) using 12–24 month LEAPS to capture AI upside while limiting cash outlay; if already long, sell 3-month OTM calls to harvest premium. Implement a pair trade: long ISRG vs short MDT (equal notional) to isolate robotic premium; scale in on any >20% pullback or if forward P/E contracts to ~40x. Use bull-call spreads to cap cost if implied vol spikes around earnings.

Contrarian angles: Consensus prices robust growth (P/E ~67x vs historical ~72x) but under-weights rate sensitivity and hospital-capex cyclicality — a 100bp rise in yields meaningfully lowers present value of long-dated recurring cash flows. If procedure growth sustains 12–15% and AI delivers incremental margin/penetration, ISRG could justify current multiples; conversely, commoditization of instruments or third-party consumables licensing would be an asymmetric downside. Watch for early signs of OR saturation (procedures per unit flattening) as a leading indicator of attach-rate deceleration.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ISRG using 12–24 month LEAPS (e.g., buy Jan 2028 calls) to capture multi-year AI/procedure adoption upside while limiting capital; add incrementally on any drawdown >15% from today.
• Implement a directional pair trade: go long ISRG and short MDT (Medtronic) in equal notional size (1:1) sized at 1–2% net exposure to isolate robot premium; rebalance if relative spread moves >20% in either direction.
• If already long ISRG, sell 3-month OTM covered calls at ~10–15% OTM to collect income until a clear catalyst (AI approval or earnings beat) — roll if assigned or if stock drops >20%.
• Use a defined-risk options debit spread (bull-call spread) around earnings: buy 12–18 month ITM LEAPS and sell a higher-strike LEAPS to cap cost, targeting a break-even ~20–25% above current price over 12–18 months.
• Monitor three objective triggers over the next 60–90 days before adding size: quarterly placements >+10% q/q, company surgical procedure guidance ≥12% for 2026, and any FDA AI approval announcements; if two of three fail, trim exposure by 50%.